## Supplementary Material

# Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study 

Michael Sticherling ${ }^{\text {a }}$, Tess McPherson ${ }^{\text {b }}$, Raúl de Lucas Laguna ${ }^{\text {c }}$, Antonio Costanzo ${ }^{\text {d,e }}$, Catherine Reed ${ }^{{ }^{\ddagger}}$, Esther Artime $^{\text {g }}$, Camille Robert ${ }^{\text {h }}$, James Lucas ${ }^{i}$, Christopher Schusterj, Emmanuel Mahék

> aDepartment of Dermatology, Psoriasic-Center, Deutsches Zentrum Immuntherapie (DZI), University of Erlangen, Erlangen, Germany; ${ }^{\text {b }}$ Churchill Hospital, Oxford, UK; ${ }^{\text {}}$ Servicio de Dermatología Infantil, Hospital Universitario La Paz, Madrid, Spain; dDermatology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; ${ }^{e}$ Dermatology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; ${ }^{\dagger}$ Eli Lilly and Company, Bracknell, UK; 9Eli Lilly and Company, Madrid, Spain; ${ }^{\text {hLilly France SAS, Neuilly }}$ Sur Seine, France; 'Adelphi Real-World, Macclesfield, UK; 'Eli Lilly Regional Operations GmbH, Vienna, Austria; kService de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France

[^0]Email:
reed_catherine@lilly.com

Supplementary Table 1 Number of patient report forms completed, by country.

| Country | Overall | Weighing 25-50 kg | Weighing >50 kg |
| :--- | :---: | :---: | :---: |
| Overall | 1919 | $772(40.2 \%)$ | $1147(59.8 \%)$ |
| France | 414 | $196(47.3 \%)$ | $218(52.7 \%)$ |
| Germany | 462 | $170(36.8 \%)$ | $292(63.2 \%)$ |
| Italy | 389 | $184(47.3 \%)$ | $205(52.7 \%)$ |
| Spain | 429 | $156(36.4 \%)$ | $273(63.6 \%)$ |
| UK | 225 | $66(29.3 \%)$ | $159(70.7 \%)$ |

Supplementary Table 2 Patient characteristics and history of psoriasis at the time of data collection, by country and weight category.

| Parameter ${ }^{\text {a }}$ | France |  |  | Germany |  |  | Italy |  |  | Spain |  |  | UK |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Overall | 25-50 kg | >50 kg | Overall | 25-50 kg | >50 kg | Overall | 25-50 kg | >50 kg | Overall | 25-50 kg | >50 kg | Overall | $25-50 \mathrm{~kg}$ | >50 kg |
| Number and percentage of patients | 414 | 196 (47.3\%) | 218 (52.7\%) | 462 | 170 (36.8\%) | 292 (63.2\%) | 389 | 184 (47.3\%) | 205 (52.7\%) | 429 | 156 (36.4\%) | 273 (63.6\%) | 225 | 66 (29.3\%) | 159 (70.7\%) |
| Current age (years) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mean $\pm$ SD | $14.1 \pm 2.9$ | $12.3 \pm 3.0$ | $15.6 \pm 1.7$ | $13.7 \pm 2.9$ | $10.9 \pm 2.5$ | $15.4 \pm 1.5$ | $13.2 \pm 3.1$ | $11.0 \pm 2.8$ | $15.1 \pm 1.7$ | $14.2 \pm 2.9$ | $11.6 \pm 2.8$ | $15.6 \pm 1.6$ | $14.4 \pm 2.6$ | $11.5 \pm 2.5$ | $15.6 \pm 1.4$ |
| Median [IQR] | $\begin{gathered} 15.0[12.0, \\ 16.0] \\ \hline \end{gathered}$ | $\begin{gathered} 13.0[10.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 16.0[15.0, \\ 17.0] \\ \hline \end{gathered}$ | $\begin{gathered} 15.0[12.0, \\ 16.0] \\ \hline \end{gathered}$ | $\begin{gathered} 11.0[9.0, \\ 12.0] \\ \hline \end{gathered}$ | $\begin{gathered} 16.0[14.0 \\ 16.0] \\ \hline \end{gathered}$ | $\begin{gathered} 14.0[11.0 \\ 16.0] \\ \hline \end{gathered}$ | $\begin{gathered} 11.0[9.0, \\ 13.0] \\ \hline \end{gathered}$ | $\begin{gathered} 16.0[14.0, \\ 16.0] \\ \hline \end{gathered}$ | $\begin{gathered} 15.0[12.0 \\ 16.0] \\ \hline \end{gathered}$ | $\begin{gathered} 12.0[10.0, \\ 14.0] \\ \hline \end{gathered}$ | $\begin{gathered} 16.0[15.0, \\ 17.0] \\ \hline \end{gathered}$ | $\begin{gathered} 15.0[13.0, \\ 16.0] \\ \hline \end{gathered}$ | $\begin{gathered} 11.0[9.0, \\ 13.0] \\ \hline \end{gathered}$ | $\begin{gathered} 16.0[15.0, \\ 17.0] \\ \hline \end{gathered}$ |
| Male | 230 (55.6\%) | 78 (39.8\%) | 152 (69.7\%) | 266 (57.6\%) | 83 (48.8\%) | 183 (62.7\%) | 229 (58.9\%) | 86 (46.7\%) | 143 (69.8\%) | 240 (55.9\%) | 70 (44.9\%) | 170 (62.3\%) | 126 (56.0\%) | 35 (53.0\%) | 91 (57.2\%) |
| Current body mass index |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mean $\pm$ SD | $21.1 \pm 6.0$ | $19.6 \pm 5.4$ | $22.5 \pm 6.2$ | $21.1 \pm 2.7$ | $19.1 \pm 2.3$ | $22.3 \pm 2.3$ | $21.4 \pm 9.3$ | $19.7 \pm 3.1$ | $22.9 \pm 12.2$ | $23.0 \pm 10.9$ | $21.0 \pm 12.5$ | $24.2 \pm 9.8$ | $23.8 \pm 10.6$ | $20.2 \pm 6.9$ | $25.3 \pm 11.5$ |
| Median [IQR] | $\begin{gathered} 20.3[19.0, \\ 22.0] \\ \hline \end{gathered}$ | $\begin{gathered} 18.7[18.0, \\ 20.0] \\ \hline \end{gathered}$ | $\begin{gathered} 22.0[20.0, \\ 24.0] \\ \hline \end{gathered}$ | $\begin{gathered} 21.0[19.0, \\ 23.0] \\ \hline \end{gathered}$ | $\begin{gathered} 18.8[18.0, \\ 20.0] \\ \hline \end{gathered}$ | $\begin{gathered} 22.0[21.0 \\ 23.0] \\ \hline \end{gathered}$ | $\begin{gathered} 20.8[19.0, \\ 23.0] \\ \hline \end{gathered}$ | $\begin{gathered} 19.2[18.0, \\ 21.0] \\ \hline \end{gathered}$ | $\begin{gathered} 22.6[21.0, \\ 24.0] \\ \hline \end{gathered}$ | $\begin{gathered} 21.6[20.0, \\ 24.0] \\ \hline \end{gathered}$ | $\begin{gathered} 19.3[18.0, \\ 21.0] \\ \hline \end{gathered}$ | $\begin{gathered} 22.7[21.0, \\ 25.0] \\ \hline \end{gathered}$ | $\begin{gathered} 22.1[20.0, \\ 24.0] \\ \hline \end{gathered}$ | $\begin{gathered} 19.2[18.0, \\ 20.0] \\ \hline \end{gathered}$ | $\begin{gathered} 23.4[21.0, \\ 27.0] \\ \hline \end{gathered}$ |
| Type of psoriasis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Plaque | 371 (89.6\%) | 177 (90.3\%) | 194 (89.0\%) | 445 (96.3\%) | 165 (97.1\%) | 280 (95.9\%) | 326 (83.8\%) | 153 (83.2\%) | 173 (84.4\%) | 386 (90.0\%) | 140 (89.7\%) | 246 (90.1\%) | 206 (91.6\%) | 59 (89.4\%) | 147 (92.5\%) |
| Other | 43 (10.4\%) | 19 (9.7\%) | 24 (11.0\%) | 17 (3.7\%) | 5 (2.9\%) | 12 (4.1\%) | 63 (16.2\%) | 31 (16.8\%) | 32 (15.6\%) | 43 (10.0\%) | 16 (10.3\%) | 27 (9.9\%) | 19 (8.4\%) | 7 (10.6\%) | 12 (7.5\%) |
| Age at diagnosis (years) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mean $\pm$ SD | $10.8 \pm 3.6$ | $9.7 \pm 3.2$ | $11.8 \pm 3.6$ | $11.9 \pm 3.1$ | $9.7 \pm 2.3$ | $13.5 \pm 2.6$ | $11.0 \pm 3.1$ | $9.3 \pm 2.7$ | $12.7 \pm 2.6$ | $11.5 \pm 3.9$ | $9.1 \pm 3.3$ | $12.9 \pm 3.6$ | $12.1 \pm 3.1$ | $9.0 \pm 2.4$ | $13.3 \pm 2.5$ |
| Median [IQR] | $\begin{gathered} 11.0[8.0, \\ 14.0] \\ \hline \end{gathered}$ | $\begin{gathered} 10.0[8.0, \\ 12.0] \\ \hline \end{gathered}$ | $\begin{gathered} 13.0[10.0 \\ 14.0] \\ \hline \end{gathered}$ | $\begin{gathered} 12.0[10.0, \\ 15.0] \end{gathered}$ | $\begin{gathered} 10.0[8.0, \\ 11.0] \\ \hline \end{gathered}$ | $\begin{gathered} 14.0[12.0 \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 11.0[9.0, \\ 13.0] \end{gathered}$ | $\begin{gathered} 9.0[7.0, \\ 11.0] \end{gathered}$ | $\begin{gathered} 13.0[11.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 12.0[9.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 9.0[7.0, \\ 11.0] \\ \hline \end{gathered}$ | $\begin{gathered} 14.0[11.0, \\ 16.0] \end{gathered}$ | $\begin{gathered} 13.0[9.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{array}{r} 9.0[7.0, \\ 11.0] \\ \hline \end{array}$ | $\begin{gathered} 14.0[12.0 \\ 15.0] \\ \hline \end{gathered}$ |
| Time since diagnosis (years) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mean $\pm$ SD | $3.5 \pm 3.2$ | $2.9 \pm 2.8$ | $4.1 \pm 3.5$ | $1.9 \pm 2.2$ | $1.3 \pm 1.5$ | $2.3 \pm 2.4$ | $2.3 \pm 2.2$ | $1.9 \pm 2.1$ | $2.7 \pm 2.3$ | $3.0 \pm 3.0$ | $2.7 \pm 2.7$ | $3.1 \pm 3.2$ | $2.5 \pm 2.1$ | $2.5 \pm 1.8$ | $2.6 \pm 2.3$ |
| Median [IQR] | $\begin{array}{r} 2.5[1.1, \\ 5.1] \\ \hline \end{array}$ | $\begin{gathered} 2.2[0.5, \\ 4.8] \\ \hline \end{gathered}$ | $\begin{gathered} 3.1[1.5, \\ 5.7] \\ \hline \end{gathered}$ | $\begin{array}{r} 1.1[0.5,5 \\ 2.6] \\ \hline \end{array}$ | $\begin{gathered} 0.8[0.4, \\ 1.7] \\ \hline \end{gathered}$ | $\begin{array}{r} 1.4[0.5, \\ 3.2] \\ \hline \end{array}$ | $\begin{gathered} 1.6[0.6, \\ 3.1] \\ \hline \end{gathered}$ | $\begin{array}{r} 1.3[0.5, \\ 2.6] \\ \hline \end{array}$ | $\begin{gathered} 2.1[1.1, \\ 4.1] \\ \hline \end{gathered}$ | $\begin{gathered} 2.0[1.0, \\ 4.0] \\ \hline \end{gathered}$ | $\begin{gathered} 2.1[1.0, \\ 3.9] \\ \hline \end{gathered}$ | $\begin{gathered} 2.0[1.1, \\ 4.1] \\ \hline \end{gathered}$ | $\begin{gathered} 1.9[1.1, \\ 3.4] \\ \hline \end{gathered}$ | $\begin{gathered} 2.2[1.1, \\ 3.3] \\ \hline \end{gathered}$ | $\begin{gathered} 1.9[1.1, \\ 3.8] \\ \hline \end{gathered}$ |
| Severity of psoriasis at diagnosis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |


| Mild <br> Moderate/Severe | $\begin{array}{r} 87 \text { (21.0\%) } \\ 327 \text { (79.0\%) } \end{array}$ | $\begin{gathered} 46 \text { (23.5\%) } \\ 150(76.5 \%) \end{gathered}$ | $\begin{array}{r} 41 \text { (18.8\%) } \\ 177 \text { (81.2\%) } \\ \hline \end{array}$ | $\begin{aligned} & 220(47.6 \%) \\ & 242(52.4 \%) \end{aligned}$ | $\begin{aligned} & 76 \text { (44.7\%) } \\ & 94 \text { (55.3\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 144 \text { (49.3\%) } \\ & 148 \text { (50.7\%) } \end{aligned}$ | $\begin{aligned} & 113 \text { (29.0\%) } \\ & 276 \text { (71.0\%) } \end{aligned}$ | $\begin{gathered} 66 \text { (35.9\%) } \\ 118 \text { (64.1\%) } \end{gathered}$ | $\begin{gathered} 47 \text { (22.9\%) } \\ 158 \text { (77.1\%) } \end{gathered}$ | $\begin{aligned} & 157 \text { (36.6\%) } \\ & 272 \text { (63.4\%) } \\ & \hline \end{aligned}$ | $\begin{aligned} & 76 \text { (48.7\%) } \\ & 80(51.3 \%) \\ & \hline \end{aligned}$ | $\begin{gathered} 81 \text { (29.7\%) } \\ 192 \text { (70.3\%) } \end{gathered}$ | $\begin{gathered} 64 \text { (28.4\%) } \\ 161 \text { (71.6\%) } \end{gathered}$ | $\begin{array}{r} 31 \text { (47.0\%) } \\ 35 \text { (53.0\%) } \\ \hline \end{array}$ | $\begin{gathered} 33 \text { (20.8\%) } \\ 126 \text { (79.2\%) } \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| BSA affected at diagnosis (\%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mean $\pm$ SD | $21.0 \pm 19.6$ | $20.7 \pm 21.0$ | $21.4 \pm 18.3$ | $12.6 \pm 10.3$ | $12.5 \pm 11.0$ | $12.7 \pm 9.7$ | $21.0 \pm 17.1$ | $19.8 \pm 17.3$ | $22.2 \pm 16.9$ | $10.0 \pm 9.0$ | $8.7 \pm 8.8$ | $10.8 \pm 9.0$ | $12.0 \pm 13.0$ | $9.6 \pm 10.5$ | $13.1 \pm 13.9$ |
| Median [IQR] | $\begin{gathered} 15.0[8.0, \\ 25.0] \\ \hline \end{gathered}$ | $\begin{gathered} 14.0[8.0, \\ 22.0] \\ \hline \end{gathered}$ | $\begin{gathered} 15.0[10.0 \\ 25.0] \\ \hline \end{gathered}$ | $\begin{gathered} 10.0[8.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 10.0[6.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 10.0[8.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 15.0[8.0, \\ 30.0] \\ \hline \end{gathered}$ | $\begin{gathered} 12.5[8.0, \\ 26.0] \\ \hline \end{gathered}$ | $\begin{gathered} 18.5[8.0, \\ 35.0] \\ \hline \end{gathered}$ | $\begin{gathered} 8.0[5.0, \\ 12.0] \\ \hline \end{gathered}$ | $\begin{gathered} 7.5[4.0, \\ 10.0] \\ \hline \end{gathered}$ | $\begin{gathered} 8.0[5.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{array}{r} 9.0[5.0, \\ 15.0] \\ \hline \end{array}$ | $\begin{gathered} 5.0[2.0, \\ 15.0] \\ \hline \end{gathered}$ | $\begin{gathered} 10.0[5.0, \\ 15.0] \\ \hline \end{gathered}$ |
| Family history of psoriasis | 210 (50.7\%) | 95 (48.5\%) | 115 (52.8\%) | 154 (33.3\%) | 60 (35.3\%) | 94 (32.2\%) | 201 (51.7\%) | 85 (46.2\%) | 116 (56.6\%) | 234 (54.5\%) | 83 (53.2\%) | 151 (55.3\%) | 100 (44.4\%) | 30 (45.5\%) | 70 (44.0\%) |
| Diagnosis of psoriatic arthritis | 19 (4.6\%) | 7 (3.6\%) | 12 (5.5\%) | 20 (4.3\%) | 5 (2.9\%) | 15 (5.1\%) | 16 (4.1\%) | 4 (2.2\%) | 12 (5.9\%) | 17 (4.0\%) | 9 (5.8\%) | 8 (2.9\%) | 10 (4.4\%) | 3 (4.5\%) | 7 (4.4\%) |

Values are shown as mean $\pm$ standard deviation or $\mathrm{n}(\%)$ unless otherwise indicated.
${ }^{\text {a }}$ Number of patients was lower for some parameters.
BSA, body surface area; IQR, interquartile range; SD, standard deviation.

Supplementary Table 3 Current treatment characteristics, by type of prescriber and country

| Treatment | $\begin{aligned} & \text { Overall } \\ & (\mathrm{N}=1919) \end{aligned}$ |  |  | $\begin{aligned} & \hline \text { France } \\ & (\mathrm{N}=414) \end{aligned}$ |  |  | $\begin{aligned} & \text { Germany } \\ & (\mathrm{N}=462) \end{aligned}$ |  |  | $\begin{gathered} \hline \text { Italy } \\ (\mathrm{N}=389) \end{gathered}$ |  |  | $\begin{gathered} \text { Spain } \\ (\mathrm{N}=429) \\ \hline \end{gathered}$ |  |  | $\begin{gathered} \text { UK } \\ (\mathrm{N}=225) \end{gathered}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of prescriber | Dermatologist | Pediatrician | PCP | Dermatologist | Pediatrician | PCP | Dermatologist | Pediatrician | PCP | Dermatologist | Pediatrician | PCP | Dermatologist | Pediatrician | PCP | Dermatologist | Pediatrician | PCP |
| Number and percentage of prescribers | $\begin{gathered} 1150 \\ (59.9 \%) \end{gathered}$ | $\begin{gathered} 329 \\ (17.1 \%) \end{gathered}$ | $\begin{gathered} 440 \\ (22.9 \%) \end{gathered}$ | $\begin{gathered} 208 \\ (50.2 \%) \end{gathered}$ | $\begin{gathered} 85 \\ (20.5 \%) \end{gathered}$ | $\begin{array}{\|c\|} \hline 121 \\ (29.2 \%) \\ \hline \end{array}$ | $\begin{gathered} 270 \\ (58.4 \%) \end{gathered}$ | $\begin{gathered} 103 \\ (22.3 \%) \end{gathered}$ | $\begin{gathered} 89 \\ (19.3 \%) \end{gathered}$ | $\begin{gathered} 236 \\ (60.7 \%) \end{gathered}$ | $\begin{gathered} 99 \\ (25.4 \%) \end{gathered}$ | 54 (13.9\%) | $\begin{gathered} 302 \\ (70.4 \%) \end{gathered}$ | $\begin{gathered} \hline 42 \\ (9.8 \%) \end{gathered}$ | 85 (19.8\%) | $\begin{gathered} 134 \\ (59.6 \%) \end{gathered}$ | 0 | 91 (40.4\%) |
| Severity of psoriasis immediately prior to current/most recen treatment regimen Mild |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Moderate/Severe | $\begin{gathered} 232 \\ (20.2 \%) \\ 998 \\ (79.8 \%) \end{gathered}$ | $\begin{gathered} 122 \\ (37.1 \%) \\ 207 \\ (62.9 \%) \end{gathered}$ | $\begin{gathered} 187 \\ (42.5 \%) \\ 253 \\ (57.5 \%) \end{gathered}$ | $\begin{gathered} 19 \\ (9.1 \%) \\ 189 \\ (90.9 \%) \end{gathered}$ | $\begin{gathered} 12 \\ (14.1 \%) \\ 73 \\ (85.9 \%) \end{gathered}$ | $\left(\begin{array}{c} 28 \\ (23.1 \%) \\ 93 \\ (76.9 \%) \end{array}\right.$ | $\begin{gathered} 83 \\ (30.7 \%) \\ 187 \\ (69.3 \%) \end{gathered}$ | $\begin{gathered} 45 \\ (43.7 \%) \\ 58 \\ (56.3 \%) \end{gathered}$ | $\begin{array}{\|c\|} 52(58.4 \%) \\ 37 \\ (41.6 \%) \end{array}$ | $\begin{gathered} 37 \\ (15.7 \%) \\ 199 \\ (84.3 \%) \end{gathered}$ | $\begin{gathered} 44 \\ (44.4 \%) \\ 55 \\ (55.6 \%) \end{gathered}$ | $\begin{gathered} 19 \\ (35.2 \%) \\ 35 \\ (64.8 \%) \end{gathered}$ | $\begin{gathered} 72 \\ (23.8 \%) \\ 230 \\ (76.2 \%) \end{gathered}$ | $\begin{gathered} 21 \\ (50.0 \%) \\ 21 \\ (50.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 44 \\ (51.8 \%) \\ 41 \\ (48.2 \%) \end{gathered}$ | $\begin{gathered} 21 \\ (15.7 \%) \\ 113 \\ (84.3 \%) \end{gathered}$ | - | $\begin{gathered} 44 \\ (48.4 \%) \\ 47 \\ (51.6 \%) \end{gathered}$ |
| Current severity of psoriasis Mild <br> Moderate/Severe | $\begin{gathered} 933 \\ (81.1 \%) \\ 217 \\ (18.9 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 554 \\ (77.2 \%) \\ 75 \\ (22.8 \%) \\ \hline \end{gathered}$ | $\left\|\begin{array}{c} 349 \\ (79.3 \%) \\ 91(20.7 \%) \end{array}\right\|$ | $\begin{gathered} 159 \\ (76.4 \%) \\ 49 \\ (23.6 \%) \end{gathered}$ | $\begin{gathered} 50 \\ (58.8 \%) \\ 35 \\ (41.2 \%) \end{gathered}$ | $\begin{gathered} 78 \\ (64.5 \%) \\ 43 \\ (35.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 217 \\ (80.4 \%) \\ 53 \\ (19.6 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 90 \\ (84.4 \%) \\ 13 \\ (12.6 \%) \end{gathered}$ | $\begin{gathered} 80 \\ (89.9 \%) \\ 9 \\ (10.1 \%) \end{gathered}$ | $\begin{gathered} 196 \\ (83.1 \%) \\ 40 \\ (16.9 \%) \end{gathered}$ | $\begin{gathered} 80 \\ (80.8 \%) \\ 19 \\ (19.2 \%) \end{gathered}$ | $\begin{gathered} 40 \\ (74.1 \%) \\ 14 \\ (25.9 \%) \end{gathered}$ | $\begin{gathered} 246 \\ (84.5 \%) \\ 56 \\ (18.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 34 \\ (81.0 \%) \\ 8 \\ (19.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 76 \\ (89.4 \%) \\ 9 \\ (10.6 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 115 \\ (85.8 \%) \\ 19 \\ (14.2 \%) \end{gathered}$ | - | $\begin{gathered} 75 \\ (82.4 \%) \\ 16 \\ (17.6 \%) \end{gathered}$ |
| Topical only  <br> corticosteroid Topical | $\begin{gathered} 499 \\ (43.4 \%) \\ 301 \\ (26.2 \%) \end{gathered}$ | $\begin{gathered} 248 \\ (75.4 \%) \\ 117 \\ 35.6 \%) \end{gathered}$ | $\begin{gathered} 386 \\ (87.7 \%) \\ 230 \\ (52.3 \%) \end{gathered}$ | $\begin{gathered} 74 \\ (35.6 \%) \\ 68 \\ (32.7 \%) \end{gathered}$ | $\begin{gathered} 61 \\ (71.8 \%) \\ 20 \\ (23.5 \%) \end{gathered}$ | $\begin{array}{\|c\|} \hline 104 \\ (86.0 \%) \\ 80 \\ (66.1 \%) \end{array}$ | $\begin{gathered} 151 \\ (55.9 \%) \\ 68 \\ (25.2 \%) \end{gathered}$ | $\begin{gathered} 79 \\ (76.7 \%) \\ 38 \\ (36.9 \%) \end{gathered}$ | $\begin{gathered} 74 \\ (83.1 \%) \\ 37 \\ (41.6 \%) \end{gathered}$ | $\begin{gathered} 85 \\ (36.0 \%) \\ 49 \\ (20.8 \%) \end{gathered}$ | $\begin{gathered} 83 \\ (83.8 \%) \\ 31 \\ (31.3 \%) \end{gathered}$ | $\begin{gathered} 41 \\ (75.9 \%) \\ 24 \\ (44.4 \%) \end{gathered}$ | $\begin{gathered} 140 \\ (46.4 \%) \\ 90 \\ (29.8 \%) \end{gathered}$ | $\begin{gathered} 25 \\ (59.5 \%) \\ 28 \\ (66.7 \%) \end{gathered}$ | $\begin{gathered} 82 \\ (96.5 \%) \\ 43 \\ (50.6 \%) \end{gathered}$ | $\begin{gathered} 49 \\ (36.6 \%) \\ 26 \\ (19.4 \%) \end{gathered}$ | - | $\begin{gathered} 85 \\ (93.4 \%) \\ 46 \\ (50.5 \%) \end{gathered}$ |
| Topical noncorticosteroid Topical combination product | $\begin{gathered} 258 \\ (22.4 \%) \end{gathered}$ | $\begin{gathered} 156 \\ (47.4 \%) \end{gathered}$ | $\begin{gathered} 155 \\ (35.2 \%) \end{gathered}$ | $\begin{gathered} 39 \\ (18.8 \%) \end{gathered}$ | $\begin{gathered} 31 \\ (36.5 \%) \end{gathered}$ | $\begin{array}{\|c\|} 24 \\ (19.8 \%) \end{array}$ | $\begin{gathered} 117 \\ (43.3 \%) \end{gathered}$ | $\begin{gathered} 53 \\ (51.5 \%) \end{gathered}$ | $\begin{gathered} 49 \\ (55.1 \%) \end{gathered}$ | $\begin{gathered} 48 \\ (20.3 \%) \end{gathered}$ | $\begin{gathered} 68 \\ (68.7 \%) \end{gathered}$ | $\begin{gathered} 20 \\ (37.0 \%) \end{gathered}$ | $\begin{gathered} 29 \\ (9.6 \%) \end{gathered}$ | $\begin{gathered} 4 \\ (9.5 \%) \end{gathered}$ | $\begin{gathered} 18 \\ (21.2 \%) \end{gathered}$ | $\begin{gathered} 25 \\ \text { (18.7\%) } \end{gathered}$ | - | $\begin{gathered} 44 \\ (48.4 \%) \end{gathered}$ |
|  | $\begin{gathered} 311 \\ (27.0 \%) \end{gathered}$ | $\begin{gathered} 86 \\ (26.1 \%) \end{gathered}$ | $\begin{gathered} 101 \\ (23.0 \%) \end{gathered}$ | $\begin{gathered} 30 \\ (14.4 \%) \end{gathered}$ | $\begin{gathered} 45 \\ (52.9 \%) \end{gathered}$ | $\begin{gathered} 19 \\ (15.7 \%) \end{gathered}$ | $\begin{gathered} 80 \\ (29.6 \%) \end{gathered}$ | $\begin{gathered} 10 \\ (9.7 \%) \end{gathered}$ | $\begin{gathered} 14 \\ (15.7 \%) \end{gathered}$ | $\begin{gathered} 45 \\ (19.1 \%) \end{gathered}$ | $\begin{gathered} 17 \\ (17.2 \%) \end{gathered}$ | $\begin{gathered} 19 \\ (35.2 \%) \end{gathered}$ | $\begin{gathered} 105 \\ (34.8 \%) \end{gathered}$ | $\begin{gathered} 14 \\ (33.3 \%) \end{gathered}$ | $\begin{gathered} 26 \\ (30.6 \%) \end{gathered}$ | $\begin{gathered} 51 \%) \\ (38.1 \%) \end{gathered}$ | - | $\begin{gathered} 23 \\ (25.3 \%) \end{gathered}$ |
| Phototherapy (PUVA, UVB) | $\begin{gathered} 77 \\ (6.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} \hline 37 \\ (11.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 25 \\ (5.7 \%) \\ \hline \end{gathered}$ | $\begin{array}{r} 15 \\ (7.2 \%) \\ \hline \end{array}$ | $\begin{gathered} 8 \\ (9.4 \%) \\ \hline \end{gathered}$ | $\begin{array}{\|c\|} \hline 5 \\ \hline(4.1 \%) \\ \hline \end{array}$ | $\begin{array}{r} 21 \\ (7.8 \%) \\ \hline \end{array}$ | $\begin{gathered} 9 \\ (8.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 10 \\ (11.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 16 \\ (6.8 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 5 \\ (5.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 8 \\ (14.8 \%) \\ \hline \end{gathered}$ | $\begin{array}{r} 17 \\ (5.6 \%) \\ \hline \end{array}$ | $\begin{array}{r} 15 \\ (35.7 \%) \\ \hline \end{array}$ | $\begin{gathered} 1 \\ (1.2 \%) \end{gathered}$ | $\begin{gathered} 8 \\ (6.0 \%) \\ \hline \end{gathered}$ | - | $\begin{gathered} 1 \\ (1.1 \%) \\ \hline \end{gathered}$ |
| Conventional systemics Methotrexate | $\begin{gathered} 147 \\ (14.5 \%) \\ 96 \\ (8.5 \%) \end{gathered}$ | $\begin{gathered} 23 \\ (7.0 \%) \\ 22 \\ (6.7 \%) \end{gathered}$ | $\begin{gathered} 18 \\ (4.1 \%) \\ 12 \\ (2.7 \%) \end{gathered}$ | $\begin{gathered} 33 \\ (15.9 \%) \\ 20 \\ (9.9 \%) \end{gathered}$ | $\begin{gathered} 4 \\ (4.7 \%) \\ 3 \\ (3.6 \%) \end{gathered}$ | $\begin{array}{\|c\|} \hline 5 \\ (4.1 \%) \\ 3 \\ (2.5 \%) \end{array}$ | $\begin{gathered} 21 \\ (7.8 \%) \\ 20 \\ (7.4 \%) \end{gathered}$ | $\begin{gathered} 7 \\ (6.8 \%) \\ 7 \\ (6.8 \%) \end{gathered}$ | $\begin{gathered} 6 \\ (6.7 \%) \\ 3 \\ (3.4 \%) \end{gathered}$ | $\begin{gathered} 35 \\ (14.8 \%) \\ 8 \\ (3.5 \%) \end{gathered}$ | $\begin{gathered} 4 \\ (4.0 \%) \\ 4 \\ (4.0 \%) \end{gathered}$ | $\begin{gathered} 3 \\ (5.6 \%) \\ 3 \\ (5.6 \%) \end{gathered}$ | $\begin{gathered} 38 \\ (12.6 \%) \\ 23 \\ (7.6 \%) \end{gathered}$ | $\begin{gathered} 8 \\ (19.0 \%) \\ 8 \\ (19.0 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (1.2 \%) \\ 1 . \\ (1.2 \%) \end{gathered}$ | $\begin{gathered} 40 \\ (29.9 \%) \\ 25 \\ (18.8 \%) \end{gathered}$ | - | $\begin{gathered} 3 \\ (3.3 \%) \\ 2 \\ (2.2 \%) \end{gathered}$ |
| Cyclosporine | $\begin{gathered} 46 \\ (4.1 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (0.3 \%) \end{gathered}$ | $\begin{gathered} 3 \\ (0.7 \%) \end{gathered}$ | 2 $(1.0 \%)$ | - | $\begin{gathered} 1 \\ 1 \\ (0.8 \%) \end{gathered}$ | (7.4) | (6.8) | $\begin{gathered} 1 \\ (1.1 \%) \end{gathered}$ | $\begin{gathered} 27 \\ (11.9 \%) \end{gathered}$ | (4.0) | (5.6) |  |  | (1.28) | $\begin{gathered} 7 \\ (5.3 \%) \end{gathered}$ | - | $\begin{gathered} 1 \\ (1.1 \%) \end{gathered}$ |
| Acitretin | $\begin{gathered} 23 \\ (2.0 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (0.3 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (0.2 \%) \end{gathered}$ | $\begin{gathered} 11 \\ (5.4 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (1.2 \%) \end{gathered}$ | $\left\lvert\, \begin{gathered} 1 \\ (0.8 \%) \end{gathered}\right.$ | 0 | 0 | 0 | 0 | 0 | 0 | $\begin{gathered} 5 \\ (1.7 \%) \end{gathered}$ | 0 | 0 | $\begin{gathered} 7 \\ (5.3 \%) \end{gathered}$ | - | 0 |
| Fumarate | $\begin{gathered} 3 \\ (0.3 \%) \end{gathered}$ | 0 | $\begin{gathered} 2 \\ (0.5 \%) \\ \hline \end{gathered}$ | 0 | 0 | 0 | $\begin{gathered} 1 \\ (0.4 \%) \end{gathered}$ | 0 | $\stackrel{2}{2}$ | 0 | 0 | 0 | $\begin{gathered} 1 \\ (0.3 \%) \end{gathered}$ | 0 | 0 | $\begin{gathered} 1 \\ (0.8 \%) \end{gathered}$ |  | 0 |
| Biologics <br> Etanercept <br> Etanercept or biosimilar Adalimumab <br> Adalimumab or biosimilar <br> Ustekinumab | $\begin{gathered} 407 \\ (35.4 \%) \end{gathered}$ | $\begin{gathered} 44 \\ (13.4 \%) \end{gathered}$ | $\begin{gathered} 15 \\ (3.4 \%) \end{gathered}$ | $\begin{gathered} 90 \\ (43.3 \%) \end{gathered}$ | $\begin{gathered} 16 \\ (18.8 \%) \end{gathered}$ | $\begin{array}{c\|} 8 \\ \hline(6.6 \%) \end{array}$ | $\begin{gathered} 82 \\ (30.4 \%) \end{gathered}$ | $\begin{gathered} 9 \\ (8.7 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (1.1 \%) \end{gathered}$ | $\begin{gathered} 90 \\ (38.1 \%) \end{gathered}$ | $\begin{gathered} 9 \\ (9.1 \%) \end{gathered}$ | $\begin{gathered} 3 \\ (5.6 \%) \end{gathered}$ | $\begin{gathered} 107 \\ (35.4 \%) \end{gathered}$ | $\begin{gathered} 10 \\ (23.8 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (1.2 \%) \end{gathered}$ | $\begin{gathered} 38 \\ (28.4 \%) \end{gathered}$ | - | $\begin{gathered} 2 \\ (2.2 \%) \end{gathered}$ |
|  | $\begin{gathered} 67 \\ (5.9 \%) \end{gathered}$ | $\stackrel{9}{(2.7 \%)}$ | $\begin{gathered} 4 \\ (0.9 \%) \end{gathered}$ | $\begin{gathered} 18 \\ (8.9 \%) \end{gathered}$ | $\stackrel{5}{(6.0 \%)}$ | $\underset{(1.7 \%)}{2}$ | $\begin{gathered} 11 \\ (4.1 \%) \end{gathered}$ | 0 | 0 | $\begin{gathered} 15 \\ (6.6 \%) \end{gathered}$ | $\stackrel{2}{(2.0 \%)}$ | $\begin{gathered} 1 \\ (1.9 \%) \end{gathered}$ | $\begin{gathered} 21 \\ (7.0 \%) \end{gathered}$ | $\begin{gathered} 2 \\ (4.8 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (1.2 \%) \end{gathered}$ | $\stackrel{2}{2}$ | - | 0 |
|  | 84 | 15 | 8 | 20 | 7 | 5 | 14 | , | 0 | 23 | 2 | ${ }^{2}$ | 24 | 4 | $\stackrel{1}{1}$ | 3 |  | 0 |
|  | (190) | (4.25) | (1.6) | (90) | (\%.6) | (4.3\%) | (50) | ${ }_{6}$ | 1 | 40 | 7 | ${ }_{1}$ | 41 | 6 |  | 19 |  | 1 |
|  | (16.8\%) | (7.6\%) | (1.4\%) | (24.8\%) | (7.1\%) | (2.5\%) | (14.9\%) | (5.8\%) | (1.1\%) | (17.7\%) | (7.1\%) | (1.9\%) | (13.6\%) | (14.3\%) |  | (14.3\%) | - | (1.1\%) |


|  | $\begin{gathered} 232 \\ (20.2 \%) \\ 91 \\ (8.0 \%) \end{gathered}$ | $\begin{gathered} 26 \\ (7.9 \%) \\ 3 \\ (0.9 \%) \end{gathered}$ | $\begin{gathered} 6 \\ (1.4 \%) \\ 1 \\ (0.2 \%) \end{gathered}$ | $\begin{gathered} \hline 53 \\ (25.5 \%) \\ 17 \\ (8.4 \%) \end{gathered}$ | $\begin{gathered} \hline 6 \\ (7.1 \%) \\ 3 \\ (3.6 \%) \end{gathered}$ | $\begin{gathered} 3 \\ (2.5 \%) \\ 0 \end{gathered}$ | $\begin{gathered} \hline 50 \\ (18.5 \%) \\ 18 \\ (6.7 \%) \end{gathered}$ | $\begin{gathered} 7 \\ (6.8 \%) \\ 0 \end{gathered}$ | $\begin{gathered} 1 \\ (1.1 \%) \\ 0 \end{gathered}$ | $\begin{gathered} 59 \\ (25.0 \%) \\ 8 \\ (3.5 \%) \end{gathered}$ | $\begin{gathered} 7 \\ (7.1 \%) \\ 0 \end{gathered}$ | $\begin{gathered} 1 \\ (1.9 \%) \\ 0 \end{gathered}$ | $\begin{gathered} 44 \\ (14.6 \%) \\ 39 \\ (13.0 \%) \end{gathered}$ | $\begin{gathered} 6 \\ (14.3 \%) \\ 0 \end{gathered}$ | 0 0 | $\begin{gathered} \hline 26 \\ (19.4 \%) \\ 9 \\ (6.8 \%) \end{gathered}$ | - | $\begin{gathered} 1 \\ (1.1 \%) \\ 1 \\ (1.1 \%) \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Ever received a biologic | $\begin{gathered} 435 \\ (37.8 \%) \end{gathered}$ | $\begin{gathered} 49 \\ (14.9 \%) \end{gathered}$ | $\begin{gathered} 17 \\ (3.9 \%) \end{gathered}$ | $\begin{gathered} 99 \\ (47.6 \%) \end{gathered}$ | $\begin{gathered} 21 \\ (24.7 \%) \end{gathered}$ | $\begin{gathered} 10 \\ (8.3 \%) \end{gathered}$ | $\begin{gathered} 85 \\ (31.5 \%) \end{gathered}$ | $\stackrel{9}{9}$ | $\begin{gathered} 1 \\ (1.1 \%) \end{gathered}$ | $\begin{gathered} 97 \\ (41.1 \%) \end{gathered}$ | $\begin{gathered} 9 \\ (9.1 \%) \end{gathered}$ | $\begin{gathered} 3 \\ (5.6 \%) \end{gathered}$ | $\begin{gathered} 115 \\ (38.1 \%) \end{gathered}$ | $\begin{gathered} 10 \\ (23.8 \%) \end{gathered}$ | $\begin{gathered} 1 \\ (1.2 \%) \end{gathered}$ | $\begin{gathered} 39 \\ (29.1 \%) \end{gathered}$ | - | $\stackrel{2}{2}$ |

Values are shown as n (\%).
Values are shown as $n(\%)$.
PUVA, psoralen and ultraviolet A; UVB, ultraviolet B.

Supplementary Table 4 Current treatment characteristics, by country and weight category.

| Treatment ${ }^{\text {a }}$ | France |  |  | Germany |  |  | Italy |  |  | Spain |  |  | UK |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Overall | $25-50 \mathrm{~kg}$ | $>50 \mathrm{~kg}$ | Overall | $25-50 \mathrm{~kg}$ | $>50 \mathrm{~kg}$ | Overall | $25-50 \mathrm{~kg}$ | $>50 \mathrm{~kg}$ | Overall | $25-50 \mathrm{~kg}$ | $>50 \mathrm{~kg}$ | Overall | 25-50 kg | >50 kg |
| Number and percentage of patients | 414 | $\begin{gathered} 196 \\ (47.3 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 218 \\ (52.7 \%) \\ \hline \end{gathered}$ | 462 | $\begin{gathered} 170 \\ (36.8 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 292 \\ (63.2 \%) \\ \hline \end{gathered}$ | 389 | $\begin{gathered} 184 \\ (47.3 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 205 \\ (52.7 \%) \\ \hline \end{gathered}$ | 429 | $\begin{gathered} 156 \\ (36.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 273 \\ (63.6 \%) \\ \hline \end{gathered}$ | 225 | $\begin{gathered} 66 \\ (29.3 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 159 \\ (70.7 \%) \\ \hline \end{gathered}$ |
| Severity of psoriasis immediately prior to current/most recent treatment regimen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | $\begin{gathered} 59 \\ (14.3 \%) \end{gathered}$ | $\begin{gathered} 35 \\ (17.9 \%) \end{gathered}$ | $\begin{gathered} 24 \\ (11.0 \%) \end{gathered}$ | $\begin{gathered} 180 \\ (39.0 \%) \end{gathered}$ | $\begin{gathered} 69 \\ (40.6 \%) \end{gathered}$ | $\begin{gathered} 111 \\ (38.0 \%) \end{gathered}$ | $\begin{gathered} 100 \\ (25.7 \%) \end{gathered}$ | $\begin{gathered} 60 \\ (32.6 \%) \end{gathered}$ | $\begin{gathered} 40 \\ (19.5 \%) \end{gathered}$ | $\begin{gathered} 137 \\ (31.9 \%) \end{gathered}$ | $\begin{gathered} 68 \\ (43.6 \%) \end{gathered}$ | $\begin{gathered} 69 \\ (25.3 \%) \end{gathered}$ | $\begin{gathered} 65 \\ (28.9 \%) \end{gathered}$ | $\begin{gathered} 29 \\ (43.9 \%) \end{gathered}$ | $\begin{gathered} 36 \\ (22.6 \%) \end{gathered}$ |
| Moderate/Severe | $\begin{gathered} 355 \\ (85.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 161 \\ (82.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 194 \\ (89.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 282 \\ (61.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 101 \\ (59.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 181 \\ (62.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 289 \\ (74.3 \% \\ \hline \end{gathered}$ | $\begin{gathered} 124 \\ (67.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 165 \\ (80.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 292 \\ (68.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 88 \\ (56.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 204 \\ (74.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 160 \\ (71.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 37 \\ (56.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 123 \\ (77.4 \%) \\ \hline \end{gathered}$ |
| Current severity of psoriasis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | $\begin{gathered} 287 \\ (69.3 \%) \end{gathered}$ | $\begin{gathered} 130 \\ (66.3 \%) \end{gathered}$ | $\begin{gathered} 157 \\ (72.0 \%) \end{gathered}$ | $\begin{gathered} 387 \\ (83.8 \%) \end{gathered}$ | $\begin{gathered} 142 \\ (83.5 \%) \end{gathered}$ | $\begin{gathered} 245 \\ (83.9 \%) \end{gathered}$ | $\begin{gathered} 316 \\ (81.2 \%) \end{gathered}$ | $\begin{gathered} 155 \\ (84.2 \%) \end{gathered}$ | $\begin{gathered} 161 \\ (78.5 \%) \end{gathered}$ | $\begin{gathered} 356 \\ (83.0 \%) \end{gathered}$ | $\begin{gathered} 135 \\ (86.5 \%) \end{gathered}$ | $\begin{gathered} 221 \\ (81.0 \%) \end{gathered}$ | $\begin{gathered} 190 \\ (84.4 \%) \end{gathered}$ | $\begin{gathered} 56 \\ (84.8 \%) \end{gathered}$ | $\begin{gathered} 134 \\ (84.3 \%) \end{gathered}$ |
| Moderate/Severe | $\begin{gathered} 127 \\ (30.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 66 \\ (33.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 61 \\ (28.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 75 \\ (16.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 28 \\ (16.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 47 \\ (16.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 73 \\ (18.8 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 29 \\ (15.8 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 44 \\ (21.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 73 \\ (17.0 \%) \end{gathered}$ | $\begin{gathered} 21 \\ (13.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 52 \\ (19.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 35 \\ (15.6 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 10 \\ (15.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 25 \\ (15.7 \%) \\ \hline \end{gathered}$ |
| Topical only | $\begin{gathered} 239 \\ (57.7 \%) \end{gathered}$ | $\begin{gathered} 128 \\ (65.3 \%) \end{gathered}$ | $\begin{gathered} 111 \\ (50.9 \%) \end{gathered}$ | $\begin{gathered} 304 \\ (65.8 \%) \end{gathered}$ | $\begin{gathered} 135 \\ (79.4 \%) \end{gathered}$ | $\begin{gathered} 169 \\ (57.9 \%) \end{gathered}$ | $\begin{gathered} 209 \\ (53.7 \%) \end{gathered}$ | $\begin{gathered} 127 \\ (69.0 \%) \end{gathered}$ | $\begin{gathered} 82 \\ (40.0 \%) \end{gathered}$ | $\begin{gathered} 247 \\ (57.6 \%) \end{gathered}$ | $\begin{gathered} 104 \\ (66.7 \%) \end{gathered}$ | $\begin{gathered} 143 \\ (52.4 \%) \end{gathered}$ | $\begin{gathered} 134 \\ (59.6 \%) \end{gathered}$ | $\begin{gathered} 49 \\ (74.2 \%) \end{gathered}$ | $\begin{gathered} 85 \\ (53.5 \%) \end{gathered}$ |
| Topical corticosteroid ${ }^{\text {b }}$ | $\begin{gathered} 168 \\ (41.4 \%) \end{gathered}$ | $\begin{gathered} 90 \\ (46.4 \%) \end{gathered}$ | $\begin{gathered} 78 \\ (36.8 \%) \end{gathered}$ | $\begin{gathered} 143 \\ (31.0 \%) \end{gathered}$ | $\begin{gathered} 55 \\ (32.4 \%) \end{gathered}$ | $\begin{gathered} 88 \\ (30.2 \%) \end{gathered}$ | $\begin{gathered} 104 \\ (27.4 \%) \end{gathered}$ | $\begin{gathered} 62 \\ (34.6 \%) \end{gathered}$ | $\begin{gathered} 42 \\ (21.0 \%) \end{gathered}$ | $\begin{gathered} 161 \\ (37.6 \%) \end{gathered}$ | $\begin{gathered} 68 \\ (43.6 \%) \end{gathered}$ | $\begin{gathered} 93 \\ (34.2 \%) \end{gathered}$ | $\begin{gathered} 72 \\ (32.1 \%) \end{gathered}$ | $\begin{gathered} 25 \\ (37.9 \%) \end{gathered}$ | $\begin{gathered} 47 \\ (29.7 \%) \end{gathered}$ |
| Topical non-corticosteroid ${ }^{\text {b }}$ | $\begin{gathered} 94 \\ (23.2 \%) \end{gathered}$ | $\begin{gathered} 45 \\ (23.2 \%) \end{gathered}$ | $\begin{gathered} 49 \\ (23.1 \%) \end{gathered}$ | $\begin{gathered} 219 \\ (47.5 \%) \end{gathered}$ | $\begin{gathered} 108 \\ (63.5 \%) \end{gathered}$ | $\begin{gathered} 111 \\ (38.1 \%) \end{gathered}$ | $\begin{gathered} 136 \\ (35.9 \%) \end{gathered}$ | $\begin{gathered} 71 \\ (39.7 \%) \end{gathered}$ | $\begin{gathered} 65 \\ (32.5 \%) \end{gathered}$ | $\begin{gathered} 51 \\ (11.9 \%) \end{gathered}$ | $\begin{gathered} 17 \\ (10.9 \%) \end{gathered}$ | $\begin{gathered} 34 \\ (12.5 \%) \end{gathered}$ | $\begin{gathered} 69 \\ (30.8 \%) \end{gathered}$ | $\begin{gathered} 25 \\ (37.9 \%) \end{gathered}$ | $\begin{gathered} 44 \\ (27.8 \%) \end{gathered}$ |
| Topical combination product ${ }^{\text {b }}$ | $\begin{gathered} 94 \\ (23.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 47 \\ (24.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 47 \\ (22.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 104 \\ (22.6 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 28 \\ (16.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 76 \\ (26.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 81 \\ (21.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 38 \\ (21.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 43 \\ (21.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 145 \\ (33.9 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 57 \\ (36.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 88 \\ (32.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 74 \\ (33.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 24 \\ (36.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 50 \\ (31.6 \%) \\ \hline \end{gathered}$ |
| Phototherapy (PUVA, UVB) ${ }^{\text {b }}$ | 28 (6.9\%) | 16 (8.2\%) | 12 (5.7\%) | 40 (8.7\%) | 14 (8.2\%) | 26 (8.9\%) | 29 (7.7\%) | 12 (6.7\%) | 17 (8.5\%) | 33 (7.7\%) | 13 (8.3\%) | 20 (7.4\%) | 9 (4.0\%) | 2 (3.0\%) | 7 (4.4\%) |
| Conventional systemics | 32 (7.7\%) | 12 (6.1\%) | 20 (9.2\%) | 32 (6.9\%) | 9 (5.3\%) | 23 (7.9\%) | $\begin{gathered} 40 \\ (10.3 \%) \end{gathered}$ | 15 (8.2\%) | $\begin{gathered} 25 \\ (12.2 \%) \end{gathered}$ | 39 (9.1\%) | 15 (9.6\%) | 24 (8.8\%) | $\begin{gathered} 43 \\ (19.1 \%) \end{gathered}$ | 5 (7.6\%) | $\begin{gathered} 38 \\ (23.9 \%) \end{gathered}$ |
| Methotrexate ${ }^{\text {b }}$ | 26 (6.4\%) | 9 (4.6\%) | 17 (8.0\%) | 30 (6.5\%) | 7 (4.1\%) | 23 (7.9\%) | 15 (4.0\%) | 7 (3.9\%) | 8 (4.0\%) | 32 (7.5\%) | $\begin{gathered} 16 \\ (10.3 \%) \\ \hline \end{gathered}$ | 16 (5.9\%) | $\begin{gathered} 27 \\ (12.1 \%) \\ \hline \end{gathered}$ | 4 (6.1\%) | $\begin{gathered} 23 \\ (14.6 \%) \\ \hline \end{gathered}$ |


|  |  |  |  |  |  |  |  |  |  |  | 6 (3.8\%) |  | 8 (3.6\%) |  | 8 (5.1\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cyclosporine ${ }^{\text {b }}$ | 3 (0.7\%) | 0 | 3 (1.4\%) | 1 (0.2\%) | 1 (0.6\%) | 0 | 27 (7.1\%) | 8 (4.5\%) | 19 (9.5\%) | 11 (2.6\%) |  | 5 (1.8\%) |  | 0 |  |
| Acitretin ${ }^{\text {b }}$ | 13 (3.2\%) | 5 (2.6\%) | 8 (3.8\%) | 0 | 0 | 0 | 0 | 0 | 0 | 5 (1.2\%) | 0 | 5 (1.8\%) | 7 (3.1\%) | 1 (1.5\%) | 6 (3.8\%) |
|  | 0 | 0 | 0 | 3 (0.7\%) | 1 (0.6\%) | 2 (0.7\%) | 0 | 0 | 0 | 1 (0.2\%) | 0 |  | 1 (0.4\%) | 0 | 1 (0.6\%) |
| Biologics | $\begin{gathered} 114 \\ (27.5 \%) \end{gathered}$ | $\begin{gathered} 41 \\ (20.9 \%) \end{gathered}$ | $\begin{gathered} 73 \\ (33.5 \%) \end{gathered}$ | $\begin{gathered} 92 \\ (19.9 \%) \end{gathered}$ | 14 (8.2\%) | $\begin{gathered} 78 \\ (26.7 \%) \end{gathered}$ | $\begin{gathered} 102 \\ (26.2 \%) \end{gathered}$ | $\begin{gathered} 26 \\ (14.1 \%) \end{gathered}$ | $\begin{gathered} 76 \\ (37.1 \%) \end{gathered}$ | $\begin{gathered} 118 \\ (27.5 \%) \end{gathered}$ | $\begin{gathered} 30 \\ \text { (19.2\%) } \end{gathered}$ | $\begin{gathered} 88 \\ (32.2 \%) \end{gathered}$ | $\begin{gathered} 40 \\ (17.8 \%) \end{gathered}$ | $\begin{gathered} 10 \\ (15.2 \%) \end{gathered}$ | $\begin{gathered} 30 \\ (18.9 \%) \end{gathered}$ |
| Etanercept ${ }^{\text {b }}$ | 25 (6.2\%) | 11 (5.7\%) | 14 (6.6\%) | 11 (2.4\%) | 1 (0.6\%) | 10 (3.4\%) | 18 (4.7\%) | 3 (1.7\%) | 15 (7.5\%) | 24 (5.6\%) | 10 (6.4\%) | 14 (5.1\%) | 2 (0.9\%) | 2 (3.0\%) | 0 |
| Etanercept or biosimilar ${ }^{\text {b }}$ | 32 (7.9\%) | 16 (8.2\%) | 16 (7.5\%) | 16 (3.5\%) | 1 (0.6\%) | 15 (5.2\%) | 27 (7.1\%) | 7 (3.9\%) | $\begin{gathered} 20 \\ (10.0 \%) \end{gathered}$ | 29 (6.8\%) | 12 (7.7\%) | 17 (6.3\%) | 3 (1.3\%) | 2 (3.0\%) | 1 (0.6\%) |
| Adalimumab ${ }^{\text {b }}$ | $\begin{gathered} 59 \\ (14.5 \%) \end{gathered}$ | 16 (8.2\%) | $\begin{gathered} 43 \\ (20.3 \%) \end{gathered}$ | $\begin{gathered} 47 \\ (10.2 \%) \end{gathered}$ | 8 (4.7\%) | $\begin{gathered} 39 \\ (13.4 \%) \end{gathered}$ | $\begin{gathered} 48 \\ (12.7 \%) \end{gathered}$ | 16 (8.9\%) | $\begin{gathered} 32 \\ (16.0 \%) \end{gathered}$ | $\begin{gathered} 47 \\ (11.0 \%) \end{gathered}$ | 12 (7.7\%) | $\begin{gathered} 35 \\ (12.9 \%) \end{gathered}$ | 20 (8.9\%) | 8 (12.1\%) | 12 (7.6\%) |
| Adalimumab or biosimilar ${ }^{\text {b }}$ | $\begin{gathered} 62 \\ (15.3 \%) \end{gathered}$ | 17 (8.8\%) | $\begin{gathered} 45 \\ (21.2 \%) \end{gathered}$ | $\begin{gathered} 58 \\ (12.6 \%) \end{gathered}$ | 11 (6.5\%) | $\begin{gathered} 47 \\ (16.2 \%) \end{gathered}$ | $\begin{gathered} 67 \\ (17.7 \%) \end{gathered}$ | $\begin{gathered} 18 \\ (10.1 \%) \end{gathered}$ | $\begin{gathered} 49 \\ (24.5 \%) \end{gathered}$ | $\begin{gathered} 50 \\ (11.7 \%) \end{gathered}$ | 12 (7.7\%) | $\begin{gathered} 38 \\ (14.0 \%) \end{gathered}$ | $\begin{gathered} 27 \\ (12.1 \%) \end{gathered}$ | 8 (12.1\%) | 0 |
| Ustekinumab ${ }^{\text {b }}$ | 20 (4.9\%) | 8 (4.1\%) | 12 (5.7\%) | 18 (3.9\%) | 2 (1.2\%) | 16 (5.5\%) | 8 (2.1\%) | 1 (0.6\%) | 7 (3.5\%) | 39 (9.1\%) | 6 (3.8\%) | $\begin{gathered} 33 \\ (12.1 \%) \\ \hline \end{gathered}$ | 10 (4.5\%) | 0 | 10 (6.3\%) |
| Ever received a biologic | $\begin{gathered} 130 \\ (31.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 47 \\ (24.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 83 \\ (38.1 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 95 \\ (20.6 \%) \\ \hline \end{gathered}$ | 14 (8.2\%) | $\begin{gathered} 81 \\ (27.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 109 \\ (28.0 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 30 \\ (16.3 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 79 \\ (38.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 126 \\ (29.4 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 34 \\ (21.8 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 92 \\ (33.7 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 41 \\ (18.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 10 \\ (15.2 \%) \\ \hline \end{gathered}$ | $\begin{gathered} 31 \\ (19.5 \%) \\ \hline \end{gathered}$ |

Values are shown as n (\%).
a Number of patients was lower for some parameters.
${ }^{\text {b }}$ Percentages based on the number of patients with a treatment history: number of patients with a treatment history overall, for patients weighing 25-50 kg and for patients weighing $>50 \mathrm{~kg}=406,194,212$ for France; 461, 170, 291 for Germany; 379, 179, 200 for Italy; 428, 156, 272 for Spain; and 224, 66, 158 for the UK.
PUVA, psoralen and ultraviolet A; UVB, ultraviolet B.

Supplementary Table 5 Length of time in weeks on biologic treatment for patients currently taking biologics, overall and by weight category for each country.

| Country | Overall | Weighing 25-50 kg | Weighing $>50 \mathrm{~kg}$ |
| :---: | :---: | :---: | :---: |
| France <br> n <br> Mean $\pm$ SD <br> Median [IQR] | $\begin{gathered} 112 \\ 34.3 \pm 28.2 \\ 24.0[16.0,48.0] \end{gathered}$ | $\begin{gathered} 40 \\ 27.0 \pm 21.8 \\ 18.0[12.0,41.0] \\ \hline \end{gathered}$ | $\begin{gathered} 72 \\ 38.3 \pm 30.6 \\ 30.0[16.0,52.0] \\ \hline \end{gathered}$ |
| Germany <br> n <br> Mean $\pm$ SD <br> Median [IQR] | 91 $\begin{gathered} 26.1 \pm 22.3 \\ 20.0[10.0,36.0] \end{gathered}$ | $\begin{gathered} 14 \\ 28.2 \pm 19.0 \\ 21.5[14.0,47.0] \end{gathered}$ | $\begin{gathered} 77 \\ 25.7 \pm 23.0 \\ 20.0[10.0,36.0] \end{gathered}$ |
| Italy <br> n <br> Mean $\pm$ SD <br> Median [IQR] | $\begin{gathered} 102 \\ 35.7 \pm 29.3 \\ 24.0[12.0,50.0] \end{gathered}$ | $\begin{gathered} 26 \\ 39.2 \pm 27.2 \\ 35.0[12.0,52.0] \end{gathered}$ | $\begin{gathered} 76 \\ 34.6 \pm 39.9 \\ 24.0[12.0,48.0] \end{gathered}$ |
| Spain <br> n <br> Mean $\pm$ SD <br> Median [IQR | $\begin{gathered} 118 \\ 32.7 \pm 29.8 \\ 24.0[12.0,50.0] \end{gathered}$ | $\begin{gathered} 30 \\ 40.0 \pm 34.2 \\ 31.0[12.0,52.0] \end{gathered}$ | $\begin{gathered} 88 \\ 30.2 \pm 19.8 \\ 24.0[12.0,48.0] \end{gathered}$ |
| UK <br> n <br> Mean $\pm$ SD <br> Median [IQR] | $\begin{gathered} 40 \\ 37.4 \pm 16.9 \\ 35.5[24.0,52.0] \end{gathered}$ | $\begin{gathered} 10 \\ 36.1 \pm 17.3 \\ 35.0[22.0,52.0] \end{gathered}$ | $\begin{gathered} 30 \\ 37.9 \pm 17.1 \\ 35.5[24.0,52.0] \end{gathered}$ |

IQR, interquartile range; SD, standard deviation.

Supplementary Fig. 1
Number and percentage of physicians participating in the survey, by country. PCP, primary care physician.


Supplementary Fig. 2
Treatments received according to disease severity prior to the initiation of current treatment, by weight category for (a) France, (b) Germany, (c) Italy, (d) Spain, and (e) the UK.
(a) France


Weighing 25-50 kg


(b) Germany



(c) Italy



Weighing >50 kg

(d) Spain

(e) UK




Supplementary Fig. 3
Age of patients at biologic initiation, presented as the percentage of patients in each year group, overall and by country. Percentages are slightly under or over 100\% due to rounding.


Supplementary Fig. 4
Current (a) weight and (b) body mass index (BMI) of patients receiving biologics, presented as the percentage of patients in each weight/BMI category, overall and by country. Percentages are slightly under or over $100 \%$ due to rounding.
(a)

(b)


Supplementary Fig. 5
Treatments by line of therapy and disease severity at treatment initiation for patients with a complete treatment history for the overall patient population in each country. Percentages for each regimen line add up to $>100 \%$ as patients could receive multiple treatments for each regimen line.
(a) France

(b) Germany

(c) Italy

(d) Spain

(e) UK



[^0]:    *Corresponding Author: Catherine Reed

